PRILOSEC (omeprazole) by AstraZeneca is proton pump inhibitors [moa]. First approved in 1989.
Drug data last refreshed 8h ago · AI intelligence enriched 2d ago
PRILOSEC (omeprazole) is a proton pump inhibitor (PPI) that reduces gastric acid production by blocking H+/K+-ATPase in parietal cells. It is indicated for gastroesophageal reflux disease (GERD), peptic ulcer disease, and acid-related conditions. The drug is available as an oral delayed-release capsule and has been a cornerstone of acid-suppression therapy since FDA approval in 1989.
As LOE approaches, brand roles are contracting; focus shifts to generics optimization and specialty indications to extend franchise value.
Proton Pump Inhibitors
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Evaluate the Effects of Low-Fat Meal, High-Fat Meal and Omeprazole Enteric-Coated Tablets on the Pharmacokinetics of ABSK-011 Capsules in Healthy Participants
Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants
A Study to Learn if Taking BIIB141 (Omaveloxolone) Affects How Omeprazole is Processed in the Body and About BIIB141's Safety in Healthy Adults Aged 18 to 55
Effects of Omeprazole Ingestion on Postprandial Amino Acid Concentrations in Response to a Mixed Meal
A Study of Food Effect and Esomeprazole on LY4064809 in Healthy Adult Participants
Worked on PRILOSEC at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on PRILOSEC offers stability in a mature, well-understood market but limited growth opportunity. Roles emphasize defensive strategies, cost management, and OTC transition rather than innovation; careers here suit those seeking operational excellence or transitioning into related therapeutic areas.